Lumicell

Lumicell is a biotechnology company focused on advanced cancer imaging technology, particularly aimed at improving surgical outcomes in cancer treatment, starting with breast cancer. The company’s mission is to enhance surgical oncology by enabling surgeons to detect and remove cancerous tissue more effectively and in real-time during procedures. The core innovation of Lumicell is its fluorescence-guided imaging platform, which includes LUMISIGHT™, a proprietary optical imaging agent, and the Lumicell Direct Visualization System (DVS). This system provides surgeons with real-time visualization of residual cancer cells during lumpectomy procedures, achieving an 84% diagnostic accuracy in detecting residual breast cancer. Lumicell is also expanding its technology to address other solid tumors, including prostate, colorectal, and lung cancers. Lumicell has received significant regulatory recognition, including FDA Fast Track and Breakthrough Device designations, and has obtained FDA approval for its imaging platform in breast cancer surgery. The company aims to improve patient outcomes by reducing positive surgical margins and the need for repeat surgeries, reflecting a strong commitment to patient care.

• Employees 55
• Founded 2009
• Annual Revenue $18000000
• Total Funding $313354634